import { GuidelineSection } from '../../types';

export const specialCircumstances: GuidelineSection[] = [
  {
    title: "Special Circumstances",
    id: "special-circumstances",
    content: [],
    subsections: [
      {
        title: "Pediatric Patients",
        id: "special-circumstances-pediatric",
        content: [
          {
            statement: "Obtain a comprehensive, systematic noninvasive SCD risk assessment at initial evaluation and every 1-2 years thereafter, including evaluation of the following risk factors, in pediatric and adolescent patients with HCM: personal history of cardiac arrest or sustained ventricular arrhythmia, personal history of syncope suspected by clinical history to be arrhythmic, family history in a close relative of premature HCM-related sudden death, cardiac arrest, or sustained ventricular arrhythmia, maximal LV wall thickness, ejection fraction, LV apical aneurysm, nonsustained VT episodes on continuous ambulatory ECG monitoring.",
            level: "B",
            source: "ACC/AHA/AMSSM/SCMR 2024"
          },
          {
            statement: "Obtain repeat TTE every 1-2 years to assess the degree of myocardial hypertrophy, dynamic LVOTO, MR, and myocardial function in patients with HCM having no change in clinical status or events.",
            level: "B",
            source: "ACC/AHA/AMSSM/SCMR 2024"
          },
          {
            statement: "Consider obtaining cardiac MRI to assess for the extent of myocardial fibrosis with late gadolinium enhancement in pediatric and adolescent patients with HCM having a borderline risk for SCD, or if a decision to proceed with ICD implantation remains uncertain after a clinical assessment that includes personal and family history, echocardiography, and ambulatory ECG monitoring.",
            level: "B",
            source: "ACC/AHA/AMSSM/SCMR 2024"
          },
          {
            statement: "Consider calculating an estimated 5-year sudden death risk, including echocardiographic parameters (interventricular septal thickness in diastole, LV posterior wall thickness in end-diastole, LA diameter, maximal LVOT gradient) and genotype, to be used for shared decision-making for ICD implantation in patients aged < 16 years with HCM.",
            level: "C",
            source: "ACC/AHA/AMSSM/SCMR 2024"
          },
          {
            statement: "Initiate antiarrhythmic drugs (amiodarone, mexiletine, sotalol) in pediatric patients with HCM and recurrent ventricular arrhythmias despite β-blocker use. Decide on the choice of agent based on age, underlying comorbidities, severity of disease, patient preferences, and balance between efficacy and safety.",
            level: "B",
            source: "ACC/AHA/AMSSM/SCMR 2024"
          },
          {
            statement: "Consider performing ICD implantation in pediatric patients with HCM having ≥ 1 conventional risk factors, including unexplained syncope, massive LVH, nonsustained VT, or family history of early HCM-related SCD, after considering the relatively high complication rates of long-term ICD implantation in younger patients.",
            level: "C",
            source: "ACC/AHA/AMSSM/SCMR 2024"
          },
          {
            statement: "Consider taking into account additional factors, such as extensive late gadolinium enhancement on contrast-enhanced cardiac MRI and systolic dysfunction, in risk stratification for ICD shared decision-making in pediatric patients with HCM.",
            level: "C",
            source: "ACC/AHA/AMSSM/SCMR 2024"
          }
        ]
      },
      {
        title: "Pregnancy Management",
        id: "special-circumstances-pregnancy",
        content: [
          {
            statement: "Obtain prenatal diagnostic testing early in pregnancy, if it is to be pursued by the family, to allow making decisions regarding continuation or coordination of pregnancy.",
            level: "B",
            source: "ESC 2023"
          },
          {
            statement: "Consider offering discussion about reproductive genetic testing options with an appropriately trained healthcare professional in all families with a genetic diagnosis.",
            level: "C",
            source: "ESC 2023"
          },
          {
            statement: "Obtain pre-pregnancy risk assessment using the modified WHO classification of maternal risk and provide counseling in all female patients.",
            level: "B",
            source: "ESC 2023"
          },
          {
            statement: "Counsel on safe and effective contraception in all females of childbearing age and their partners.",
            level: "B",
            source: "ESC 2023"
          },
          {
            statement: "Counsel on the risk of disease inheritance in all male and female patients before conception.",
            level: "B",
            source: "ESC 2023"
          },
          {
            statement: "Offer vaginal delivery in most female patients with cardiomyopathies unless there are obstetric indications for C-section, severe HF (ejection fraction < 30% or NYHA class III-IV), or severe outflow tract obstructions, as well as in female patients presenting in labor on OACs.",
            level: "B",
            source: "ESC 2023"
          },
          {
            statement: "Obtain careful review of medications for safety before pregnancy and adjust according to tolerability in pregnancy.",
            level: "B",
            source: "ESC 2023"
          },
          {
            statement: "Initiate therapeutic anticoagulation with LMWH or VKAs in patients with AF according to the stage of pregnancy.",
            level: "B",
            source: "ESC 2023"
          },
          {
            statement: "Consider continuing β-blockers during pregnancy with close follow-up of fetal growth and of the condition of the neonate if the benefits outweigh the risks.",
            level: "C",
            source: "ESC 2023"
          },
          {
            statement: "Initiate β-blockers, preferably metoprolol, in patients developing symptoms during pregnancy.",
            level: "B",
            source: "ESC 2014"
          },
          {
            statement: "Continue β-blockers, preferably metoprolol, if started before pregnancy.",
            level: "B",
            source: "ESC 2014"
          },
          {
            statement: "Monitor fetal growth and the condition of the neonate whenever β-blockers are prescribed.",
            level: "B",
            source: "ESC 2014"
          }
        ]
      },
      {
        title: "Pregnant Patients",
        id: "special-circumstances-pregnant",
        content: [
          {
            statement: "Consider counseling with clinically stable HCM wishing to become pregnant that pregnancy is generally safe as part of a shared discussion regarding potential maternal and fetal risks, and initiation of guideline-directed medical therapy.",
            level: "C",
            source: "ACC/AHA/AMSSM/SCMR 2024"
          },
          {
            statement: "Provide preconceptional and prenatal reproductive and genetic counseling in affected families with HCM.",
            level: "B",
            source: "ACC/AHA/AMSSM/SCMR 2024"
          },
          {
            statement: "Coordinate the care of pregnant patients with HCM between a cardiologist and an obstetrician. Consult with an expert in maternal-fetal medicine for high-risk patients.",
            level: "B",
            source: "ACC/AHA/AMSSM/SCMR 2024"
          },
          {
            statement: "Initiate selected β-blockers for symptoms related to outflow tract obstruction or arrhythmias in pregnant patients with HCM, with monitoring of fetal growth.",
            level: "B",
            source: "ACC/AHA/AMSSM/SCMR 2024"
          },
          {
            statement: "Recognize that mavacamten is contraindicated during pregnancy due to potential teratogenic effects.",
            level: "B",
            source: "ACC/AHA/AMSSM/SCMR 2024"
          },
          {
            statement: "Initiate LMWH or VKAs (at a maximum therapeutic dose of < 5 mg/day) for stroke prevention in pregnant patients with HCM and AF or other indications for anticoagulation.",
            level: "B",
            source: "ACC/AHA/AMSSM/SCMR 2024"
          },
          {
            statement: "Consider performing cardioversion for new or recurrent AF, particularly if symptomatic.",
            level: "C",
            source: "ACC/AHA/AMSSM/SCMR 2024"
          },
          {
            statement: "Consider obtaining serial echocardiography in pregnant patients with HCM, particularly during the second or third trimester when hemodynamic load is highest, or when clinical symptoms develop.",
            level: "C",
            source: "ACC/AHA/AMSSM/SCMR 2024"
          },
          {
            statement: "Perform vaginal delivery as the first-line delivery option in most pregnant patients with HCM.",
            level: "B",
            source: "ACC/AHA/AMSSM/SCMR 2024"
          },
          {
            statement: "Consider administering general or epidural anesthesia with precautions to avoid hypotension.",
            level: "C",
            source: "ACC/AHA/AMSSM/SCMR 2024"
          },
          {
            statement: "Consider obtaining fetal echocardiography for diagnosis of fetal HCM in the context of prenatal counseling in pregnant patients with HCM.",
            level: "C",
            source: "ACC/AHA/AMSSM/SCMR 2024"
          }
        ]
      },
      {
        title: "Athletes - Evaluation",
        id: "special-circumstances-athletes-evaluation",
        content: [
          {
            statement: "Obtain expert assessment by clinicians with genetic and sports cardiology experience in athletes with inherited cardiomyopathies, using a shared decision-making model of care.",
            level: "B",
            source: "HRS 2024"
          },
          {
            statement: "Obtain genetic testing in athletes with inherited cardiomyopathies.",
            level: "B",
            source: "HRS 2024"
          },
          {
            statement: "Obtain a maximal stress test in athletes with inherited cardiomyopathies considering return to play, or returning to play after arrhythmia treatment, to identify exercise-induced ventricular arrhythmias.",
            level: "B",
            source: "HRS 2024"
          }
        ]
      },
      {
        title: "Athletes - Return to Sport",
        id: "special-circumstances-athletes-return",
        content: [
          {
            statement: "Obtain a comprehensive evaluation and shared decision-making about sports participation with an expert professional for athletes with HCM.",
            level: "B",
            source: "ACC/AHA/AMSSM/SCMR 2024"
          },
          {
            statement: "Consider allowing participation in competitive sports of any intensity in genotype-positive, phenotype-negative patients.",
            level: "C",
            source: "ACC/AHA/AMSSM/SCMR 2024"
          },
          {
            statement: "Consider allowing participation in competitive sports in patients with HCM capable of a high level of physical performance after review by an expert provider with experience managing athletes with HCM, conducting an annual comprehensive evaluation, and using shared decision-making balancing potential benefits and risks.",
            level: "C",
            source: "ACC/AHA/AMSSM/SCMR 2024"
          },
          {
            statement: "Do not perform ICD implantation in patients with HCM for the sole purpose of participation in competitive sports.",
            level: "D",
            source: "ACC/AHA/AMSSM/SCMR 2024"
          },
          {
            statement: "Allow athletes with genotype-positive phenotype-negative HCM to return to play in conjunction with expert assessment.",
            level: "B",
            source: "HRS 2024"
          },
          {
            statement: "Obtain close follow-up with regular reassessment and ongoing risk stratification in young athletes with HCM returning to play, due to the risk of evolution of their phenotype, including in genotype-positive phenotype-negative patients.",
            level: "B",
            source: "HRS 2024"
          },
          {
            statement: "Consider allowing athletes with phenotype-positive HCM to participate in competitive sports with appropriate therapy and an emergency action plan, including access to an automated external defibrillator.",
            level: "C",
            source: "HRS 2024"
          },
          {
            statement: "Offer intentional measures to attenuate the LV obstruction in athletes with symptomatic obstructive HCM before return to play.",
            level: "B",
            source: "HRS 2024"
          },
          {
            statement: "Do not perform an ICD implantation solely to facilitate return to play in athletes with inherited cardiomyopathies.",
            level: "D",
            source: "HRS 2024"
          }
        ]
      },
      {
        title: "Patients with Negative Phenotype",
        id: "special-circumstances-negative-phenotype",
        content: [
          {
            statement: "Obtain serial clinical assessment, ECG, and cardiac imaging at periodic intervals depending on age (every 1-2 years in children and adolescents and every 3-5 years in adults) and change in clinical status in genotype-positive, phenotype-negative patients.",
            level: "B",
            source: "ACC/AHA/AMSSM/SCMR 2024"
          },
          {
            statement: "Consider allowing participation in competitive sports of any intensity in genotype-positive, phenotype-negative patients.",
            level: "C",
            source: "ACC/AHA/AMSSM/SCMR 2024"
          },
          {
            statement: "Do not perform ICD implantation for primary prevention in genotype-positive, phenotype-negative patients.",
            level: "D",
            source: "ACC/AHA/AMSSM/SCMR 2024"
          }
        ]
      },
      {
        title: "Noncardiac Surgery",
        id: "special-circumstances-noncardiac-surgery",
        content: [
          {
            statement: "Avoid factors aggravating or triggering dynamic outflow obstructions, such as positive inotropic agents, tachycardia, or reduced preload, to reduce the risk of hemodynamic instability in patients with HCM undergoing noncardiac surgery.",
            level: "D",
            source: "ACC/ACS/AHA/SVM 2024"
          },
          {
            statement: "Obtain perioperative ECG monitoring in all patients with cardiomyopathy undergoing noncardiac surgery.",
            level: "B",
            source: "ESC 2023"
          },
          {
            statement: "Re-evaluate LV function with echocardiography (assessing LVOTO in patients with HCM) and measurement of NT-proBNP/BNP levels (unless recently obtained) in patients with cardiomyopathy and suspected or known HF scheduled for intermediate or high-risk noncardiac surgery.",
            level: "B",
            source: "ESC 2023"
          },
          {
            statement: "Refer patients with cardiomyopathy with high-risk genotypes or associated factors for arrhythmic or HF complications or severe LVOTO to a cardiomyopathy unit for additional specialized investigations before undergoing elective noncardiac surgery.",
            level: "B",
            source: "ESC 2023"
          },
          {
            statement: "Obtain an ECG and TTE before noncardiac surgery, regardless of symptoms, in < 65 years old patients with a first-degree relative with cardiomyopathy.",
            level: "B",
            source: "ESC 2023"
          }
        ]
      },
      {
        title: "Genetic Counseling",
        id: "special-circumstances-genetic-counseling",
        content: [
          {
            statement: "Provide genetic counseling (by an expert in the genetics of CVD) to patients with HCM regarding the risks, benefits, test results, and their clinical significance in a shared decision-making process.",
            level: "B",
            source: "ACC/AHA/AMSSM/SCMR 2024"
          },
          {
            statement: "Provide genetic counseling by an appropriately trained healthcare professional, including genetic education, to inform decision-making and psychosocial support in families with an inherited or suspected inherited cardiomyopathy, regardless of whether genetic testing is being considered.",
            level: "B",
            source: "ESC 2023"
          },
          {
            statement: "Provide pre- and post-test genetic counseling in all individuals undergoing genetic testing for cardiomyopathy.",
            level: "B",
            source: "ESC 2023"
          }
        ]
      },
      {
        title: "High-Risk Occupations",
        id: "special-circumstances-high-risk-occupations",
        content: [
          {
            statement: "Consider following the national regulations for driving permissions in patients with HCM (such as the Federal Motor Carrier Safety Administration CVD guidelines permitting driving commercial motor vehicles in patients not having an ICD or any major risk factors for SCD and following a guideline-directed management plan).",
            level: "C",
            source: "ACC/AHA/AMSSM/SCMR 2024"
          },
          {
            statement: "Consider following the national regulations for piloting permissions in patients with HCM (such as the Federal Aviation Administration guidelines for pilot aircrew permitting consideration of multi-crew flying duties, provided they are asymptomatic, are deemed low risk for SCD, and can complete a maximal treadmill stress test at 85% peak HR).",
            level: "C",
            source: "ACC/AHA/AMSSM/SCMR 2024"
          },
          {
            statement: "Consider advising patients with HCM that they can engage in occupations requiring manual labor, heavy lifting, or a high level of physical performance after a comprehensive clinical evaluation, risk stratification for SCD, and implementation of guideline-directed medical therapy in the context of shared decision-making.",
            level: "C",
            source: "ACC/AHA/AMSSM/SCMR 2024"
          }
        ]
      },
      {
        title: "Follow-up and Surveillance - Clinical",
        id: "special-circumstances-followup-clinical",
        content: [
          {
            statement: "Consider consulting with or referring to a comprehensive or primary HCM center to aid in complex disease-related management decisions.",
            level: "C",
            source: "ACC/AHA/AMSSM/SCMR 2024"
          },
          {
            statement: "Refer patients with an uncertain diagnosis, severe symptoms, or increased risk for disease-related complications to specialist teams for further investigation and management.",
            level: "B",
            source: "ESC 2014"
          },
          {
            statement: "Consider evaluating patients in centers with multidisciplinary teams with expertise in the diagnosis, genetics, risk stratification, and management of heart muscle disease in all cases of HCM.",
            level: "C",
            source: "ESC 2014"
          },
          {
            statement: "Obtain a comprehensive, systematic noninvasive SCD risk assessment every 1-2 years, including evaluation of the following risk factors, in adult patients with HCM: personal history of cardiac arrest or sustained ventricular arrhythmia, personal history of syncope suspected by clinical history to be arrhythmic, family history in a close relative of premature HCM-related sudden death, cardiac arrest, or sustained ventricular arrhythmia, maximal LV wall thickness, ejection fraction, LV apical aneurysm, nonsustained VT episodes on continuous ambulatory ECG monitoring.",
            level: "B",
            source: "ACC/AHA/AMSSM/SCMR 2024"
          },
          {
            statement: "Obtain regular clinical surveillance in patients with HCM, irrespective of symptom status, and in their first-degree relatives when appropriate.",
            level: "B",
            source: "ESC 2014"
          },
          {
            statement: "Reassess the 5-year risk of SCD at 1-2-year intervals or whenever there is a change in clinical status.",
            level: "B",
            source: "ESC 2014"
          }
        ]
      },
      {
        title: "Follow-up and Surveillance - Diagnostic Testing",
        id: "special-circumstances-followup-testing",
        content: [
          {
            statement: "Obtain periodic 12-lead ECG every 1-2 years in patients with HCM.",
            level: "B",
            source: "ACC/AHA/AMSSM/SCMR 2024"
          },
          {
            statement: "Obtain 24-48-hour ambulatory ECG monitoring every 1-2 years in patients with HCM to identify patients at risk for SCD and to guide management of arrhythmias.",
            level: "B",
            source: "ACC/AHA/AMSSM/SCMR 2024"
          },
          {
            statement: "Obtain extended ambulatory monitoring every year to screen for AF in patients with HCM deemed to be at high risk for developing AF based on the presence of risk factors or as determined by a validated risk score, and eligible for anticoagulation.",
            level: "B",
            source: "ACC/AHA/AMSSM/SCMR 2024"
          },
          {
            statement: "Consider obtaining extended ambulatory monitoring to assess for asymptomatic paroxysmal AF every 1-2 years in adult patients with HCM without risk factors for AF and eligible for anticoagulation.",
            level: "C",
            source: "ACC/AHA/AMSSM/SCMR 2024"
          },
          {
            statement: "Obtain repeat TTE every 1-2 years to assess the degree of myocardial hypertrophy, dynamic LVOTO, MR, and myocardial function in patients with HCM having no change in clinical status or events.",
            level: "B",
            source: "ACC/AHA/AMSSM/SCMR 2024"
          },
          {
            statement: "Obtain repeat TTE in patients with HCM experiencing a change in clinical status or a new clinical event.",
            level: "B",
            source: "ACC/AHA/AMSSM/SCMR 2024"
          },
          {
            statement: "Obtain a TTE within 3-6 months after septal reduction therapy to assess the procedural results.",
            level: "B",
            source: "ACC/AHA/AMSSM/SCMR 2024"
          },
          {
            statement: "Consider obtaining repeat contrast-enhanced cardiovascular MRI on a periodic basis (every 3-5 years) for SCD risk stratification to evaluate changes in late gadolinium enhancement and other morphologic changes, including ejection fraction, development of apical aneurysm, or LV wall thickness, in patients with HCM.",
            level: "C",
            source: "ACC/AHA/AMSSM/SCMR 2024"
          },
          {
            statement: "Consider obtaining exercise stress testing every 2-3 years in patients with HCM if functional capacity decline is unclear.",
            level: "C",
            source: "ACC/AHA/AMSSM/SCMR 2024"
          },
          {
            statement: "Consider obtaining symptom-limited exercise testing every 2-3 years in clinically stable patients, or every year in patients with progressive symptoms.",
            level: "C",
            source: "ESC 2014"
          },
          {
            statement: "Consider performing cardiopulmonary exercise testing (when available) every 2-3 years in clinically stable patients, or every year in patients with progressive symptoms.",
            level: "C",
            source: "ESC 2014"
          }
        ]
      },
      {
        title: "Transition to Adult Care",
        id: "special-circumstances-transition",
        content: [
          {
            statement: "Ensure timely and adequate preparation for the transition of care from pediatric to adult services, including joint consultations, for all adolescent patients with cardiomyopathy.",
            level: "B",
            source: "ESC 2023"
          }
        ]
      }
    ]
  }
]; 